FDA Commissioner Scott Gottlieb recently announced steps the agency is considering taking to encourage competition in the pharmaceutical marketplace.
Those steps, announced at a July 18 public meeting, include streamlining the generic drug review process and potentially making public letters the FDA sends to generic drug companies confirming that their use of a sample of a branded drug for purposes of demonstrating bioequivalence wouldn’t violate the branded drug’s risk evaluation and mitigation strategies (REMS). Brand drug companies sometimes use REMS safety requirements to justify holding back samples generics need to test to get regulatory approval for their products.
But some meeting participants told the FDA it must do more.
The FDA should also add REMS patents to the categories of patents ineligible for listing in the Food and Drug Administration’s Orange Book, law professor Michael A. Carrier said. Carrier is a professor at Rutgers Law School and co-director of the Rutgers Institute for Information Policy and Law in Camden, N.J.
The Orange Book is a list of patents brand-name companies claim cover their drug products and often assert to block generic entry.
Carrier also suggested that the FDA publish a list of citizen petitions filed by drug companies. Through citizen petitions, brand-name drug companies often ask the FDA to delay approving pending generic drug applications over safety concerns.
But some petitions don’t actually raise legitimate drug safety concerns and wind up delaying generic drug entry.
“Let’s see a list,” Carrier said. “That would be very helpful.”
Other meeting participants suggested the FDA should take a look at whether the alternative patent challenge proceedings at the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board could be hindering generic drug entry as well as whether certain patent exclusivities—such as the additional exclusivities awarded to orphan drugs—are also stifling competition. The FDA’s orphan drug designation, intended for drugs that treat rare conditions and diseases affecting fewer than 200,000 people in the U.S., gives special incentives to manufacturers, including tax credits, research and development funding, reduced user fees, and seven years of marketing exclusivity upon approval.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)